MGTX
MeiraGTx Holdings plc
Price Chart
Latest Quote
$11.60
-0.21 (-1.78%)
Current Price
| Previous Close | $11.81 |
| Open | $11.96 |
| Day High | $12.28 |
| Day Low | $11.54 |
| Volume | 938,026 |
Stock Information
| Shares Outstanding | 92.61M |
| Total Debt | $87.53M |
| Cash Equivalents | $71.54M |
| Revenue | $79.76M |
| Net Income | $-120.53M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.07B |
| EPS (TTM) | $-1.48 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.11B |
| Sales | $79.76M |
| Income | $-120.53M |
| Book/sh | $-0.71 |
| Cash/sh | $0.77 |
| Employees | 409 |
Financial Ratios
| Quick Ratio | 0.51 |
| Current Ratio | 0.55 |
Returns & Margins
| ROA | -28.06% |
| Gross Margin | 95.41% |
| Operating Margin | -13930.72% |
| Profit Margin | -151.12% |
Ownership
| Insider Ownership | 17.88% |
| Institutional Ownership | 60.90% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -8.34 |
| P/S | 13.47 |
| P/B | -16.25 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $28.25 |
Technical Indicators
| SMA20 | $10.01 |
| SMA50 | $9.84 |
| SMA200 | $8.47 |
| RSI | 77.56 |
| ATR | 0.6525 |
| Shares Float | 52.26M |
| Short Float | 8.25% |
| Short Ratio | 7.06 |
| Volatility | 1.26 |
| Rel Volume | 1.05 |
Performance History
| Week | +19.46% |
| Month | +25.54% |
| Quarter | +56.55% |
| 6 Months | +44.46% |
| YTD | +48.53% |
| Year | +83.84% |
| 3 Years | +54.46% |
| 5 Years | -24.23% |
| 10 Years | -22.67% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $11.60 | 938,026 |
| 2026-06-23 | $11.81 | 1,147,600 |
| 2026-06-22 | $11.48 | 1,292,700 |
| 2026-06-18 | $11.32 | 2,519,600 |
| 2026-06-17 | $10.41 | 1,013,900 |
| 2026-06-16 | $9.71 | 499,900 |
| 2026-06-15 | $9.75 | 634,600 |
| 2026-06-12 | $9.59 | 465,400 |
| 2026-06-11 | $9.60 | 876,000 |
| 2026-06-10 | $9.14 | 437,900 |
| 2026-06-09 | $9.21 | 593,000 |
| 2026-06-08 | $9.09 | 479,200 |
| 2026-06-05 | $9.00 | 693,700 |
| 2026-06-04 | $9.57 | 572,400 |
| 2026-06-03 | $9.39 | 492,700 |
| 2026-06-02 | $9.24 | 790,900 |
| 2026-06-01 | $9.80 | 757,600 |
| 2026-05-29 | $10.65 | 2,288,600 |
| 2026-05-28 | $10.00 | 704,500 |
| 2026-05-27 | $9.89 | 715,500 |
| 2026-05-26 | $9.60 | 618,000 |
About MeiraGTx Holdings plc
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ÂŊ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.
đ° Latest News
Can MeiraGTx Holdings PLC (MGTX) Stock Double? Cash Runway Offers a Hint
Insider Monkey âĸ 2026-05-20T12:36:23Z
Here's What Analysts Are Forecasting For MeiraGTx Holdings plc (NASDAQ:MGTX) After Its First-Quarter Results
Simply Wall St. âĸ 2026-05-17T13:55:02Z
MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-14T13:10:02Z
Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know
Zacks âĸ 2026-05-07T14:00:07Z
Enanta Pharmaceuticals (ENTA) Moves 5.3% Higher: Will This Strength Last?
Zacks âĸ 2026-05-07T13:02:00Z
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-07T12:50:18Z
Will MeiraGTx Holdings PLC (MGTX) Report Negative Q1 Earnings? What You Should Know
Zacks âĸ 2026-05-05T14:00:06Z
Miami International, Nathanâs Famous, and 3 More Stocks See Action From Activist Investors
Barrons.com âĸ 2026-05-01T22:18:00Z
Here is Why MeiraGTx Holdings (MGTX) is One of the Best Growth Stocks Under $10
Insider Monkey âĸ 2026-04-25T21:06:17Z
OCGN Gene Therapy Pipeline: Key 2026-27 Catalysts Ahead
Zacks âĸ 2026-04-22T16:34:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $4,843,000 | $23,791,000 | $0 | - |
| Cost Of Revenue | $4,843,000 | $23,791,000 | $0 | - |
| Total Revenue | $81,391,000 | $33,279,000 | $14,017,000 | $15,920,000 |
| Operating Revenue | $81,391,000 | $33,279,000 | $14,017,000 | $15,920,000 |
| Expenses | ||||
| Interest Expense | $12,197,000 | $13,272,000 | $13,245,000 | $4,946,000 |
| Total Expenses | $187,359,000 | $197,491,000 | $151,078,000 | $132,275,000 |
| Other Income Expense | $2,146,000 | $25,548,000 | $64,007,000 | $-9,091,000 |
| Net Non Operating Interest Income Expense | $-10,379,000 | $-9,127,000 | $-10,973,000 | $-4,169,000 |
| Interest Expense Non Operating | $12,197,000 | $13,272,000 | $13,245,000 | $4,946,000 |
| Operating Expense | $182,516,000 | $173,700,000 | $151,078,000 | $132,275,000 |
| General And Administrative Expense | $52,897,000 | $54,216,000 | $47,293,000 | $46,550,000 |
| Other Non Operating Income Expenses | - | - | $499,000 | $361,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-114,201,000 | $-147,791,000 | $-84,027,000 | $-129,615,000 |
| Net Interest Income | $-10,379,000 | $-9,127,000 | $-10,973,000 | $-4,169,000 |
| Interest Income | $1,818,000 | $4,145,000 | $2,272,000 | $777,000 |
| Normalized Income | $-116,347,000 | $-173,339,000 | $-147,535,000 | $-120,524,000 |
| Net Income From Continuing And Discontinued Operation | $-114,201,000 | $-147,791,000 | $-84,027,000 | $-129,615,000 |
| Total Operating Income As Reported | $-105,968,000 | $-164,212,000 | $-137,061,000 | $-116,355,000 |
| Net Income Common Stockholders | $-114,201,000 | $-147,791,000 | $-84,027,000 | $-129,615,000 |
| Net Income | $-114,201,000 | $-147,791,000 | $-84,027,000 | $-129,615,000 |
| Net Income Including Noncontrolling Interests | $-114,201,000 | $-147,791,000 | $-84,027,000 | $-129,615,000 |
| Net Income Continuous Operations | $-114,201,000 | $-147,791,000 | $-84,027,000 | $-129,615,000 |
| Pretax Income | $-114,201,000 | $-147,791,000 | $-84,027,000 | $-129,615,000 |
| Special Income Charges | $0 | $28,434,000 | $54,208,000 | $0 |
| Interest Income Non Operating | $1,818,000 | $4,145,000 | $2,272,000 | $777,000 |
| Operating Income | $-105,968,000 | $-164,212,000 | $-137,061,000 | $-116,355,000 |
| Gross Profit | $76,548,000 | $9,488,000 | $14,017,000 | - |
| Per Share | ||||
| Diluted EPS | $-1.42 | $-2.12 | $-1.49 | $-2.87 |
| Basic EPS | $-1.42 | $-2.12 | $-1.49 | $-2.87 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-91,544,000 | $-147,386,000 | $-120,566,000 | $-106,975,000 |
| Total Unusual Items | $2,146,000 | $25,548,000 | $63,508,000 | $-9,091,000 |
| Total Unusual Items Excluding Goodwill | $2,146,000 | $25,548,000 | $63,508,000 | $-9,091,000 |
| Reconciled Depreciation | $12,606,000 | $12,681,000 | $13,724,000 | $8,603,000 |
| EBITDA (Bullshit earnings) | $-89,398,000 | $-121,838,000 | $-57,058,000 | $-116,066,000 |
| EBIT | $-102,004,000 | $-134,519,000 | $-70,782,000 | $-124,669,000 |
| Diluted Average Shares | $80,430,186 | $69,822,353 | $56,486,525 | $45,177,857 |
| Basic Average Shares | $80,430,186 | $69,822,353 | $56,486,525 | $45,177,857 |
| Diluted NI Availto Com Stockholders | $-114,201,000 | $-147,791,000 | $-84,027,000 | $-129,615,000 |
| Gain On Sale Of Ppe | $0 | $28,434,000 | $54,208,000 | $0 |
| Gain On Sale Of Security | $2,146,000 | $-2,886,000 | $9,300,000 | $-9,091,000 |
| Research And Development | $129,619,000 | $119,484,000 | $103,785,000 | $85,725,000 |
| Selling General And Administration | $52,897,000 | $54,216,000 | $47,293,000 | $46,550,000 |
| Other Gand A | $52,897,000 | $54,216,000 | $47,293,000 | $46,550,000 |
Fetched: 2026-06-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-6,371,000 | $67,006,000 | $137,059,000 | $115,661,000 |
| Total Assets | $244,430,000 | $269,751,000 | $326,744,000 | $318,237,000 |
| Total Non Current Assets | $152,669,000 | $146,233,000 | $167,122,000 | $163,898,000 |
| Other Non Current Assets | $3,409,000 | $3,011,000 | $3,000,000 | $1,402,000 |
| Goodwill And Other Intangible Assets | $578,000 | $821,000 | $1,118,000 | $2,077,000 |
| Other Intangible Assets | $578,000 | $821,000 | $1,118,000 | $2,077,000 |
| Current Assets | $91,761,000 | $123,518,000 | $159,622,000 | $154,339,000 |
| Other Current Assets | $1,527,000 | $2,018,000 | $1,016,000 | $1,667,000 |
| Prepaid Assets | $6,017,000 | $6,828,000 | $5,625,000 | $8,133,000 |
| Inventory | $0 | $385,000 | $0 | - |
| Receivables | $18,286,000 | $10,628,000 | $23,415,000 | $29,023,000 |
| Taxes Receivable | $15,286,000 | $8,971,000 | $13,277,000 | $7,689,000 |
| Accounts Receivable | $3,000,000 | $707,000 | $10,138,000 | $21,334,000 |
| Cash Cash Equivalents And Short Term Investments | $65,931,000 | $103,659,000 | $129,566,000 | $115,516,000 |
| Cash And Cash Equivalents | $65,931,000 | $103,659,000 | $129,566,000 | $115,516,000 |
| Other Receivables | - | $950,000 | - | - |
| Debt | ||||
| Net Debt | $8,406,000 | - | - | - |
| Total Debt | $88,686,000 | $84,797,000 | $89,264,000 | $92,248,000 |
| Long Term Debt And Capital Lease Obligation | $61,149,000 | $80,744,000 | $85,071,000 | $88,364,000 |
| Long Term Debt | $49,689,000 | $73,221,000 | $72,119,000 | $71,033,000 |
| Current Debt And Capital Lease Obligation | $27,537,000 | $4,053,000 | $4,193,000 | $3,884,000 |
| Current Debt | $24,648,000 | - | - | - |
| Other Current Borrowings | $24,648,000 | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $250,223,000 | $201,924,000 | $188,567,000 | $200,499,000 |
| Total Non Current Liabilities Net Minority Interest | $127,668,000 | $141,141,000 | $121,489,000 | $118,427,000 |
| Non Current Deferred Liabilities | $65,120,000 | $57,576,000 | $34,017,000 | $27,622,000 |
| Current Liabilities | $122,555,000 | $60,783,000 | $67,078,000 | $82,072,000 |
| Other Current Liabilities | $50,283,000 | $903,000 | $1,278,000 | $6,631,000 |
| Current Deferred Liabilities | $1,776,000 | $4,827,000 | $2,926,000 | $15,123,000 |
| Payables And Accrued Expenses | $30,149,000 | $39,803,000 | $46,552,000 | $46,834,000 |
| Interest Payable | $2,710,000 | $0 | $2,936,000 | $0 |
| Payables | $10,066,000 | $23,586,000 | $16,042,000 | $16,616,000 |
| Accounts Payable | $10,066,000 | $23,586,000 | $16,042,000 | $16,616,000 |
| Non Current Deferred Taxes Liabilities | - | - | $0 | $186,000 |
| Other Non Current Liabilities | - | - | - | $262,000 |
| Equity | ||||
| Common Stock Equity | $-5,793,000 | $67,827,000 | $138,177,000 | $117,738,000 |
| Total Equity Gross Minority Interest | $-5,793,000 | $67,827,000 | $138,177,000 | $117,738,000 |
| Stockholders Equity | $-5,793,000 | $67,827,000 | $138,177,000 | $117,738,000 |
| Gains Losses Not Affecting Retained Earnings | $2,406,000 | $-3,719,000 | $-1,435,000 | $6,047,000 |
| Other Equity Adjustments | $2,406,000 | $-3,719,000 | $-1,435,000 | $6,047,000 |
| Retained Earnings | $-816,223,000 | $-702,022,000 | $-554,231,000 | $-470,204,000 |
| Long Term Equity Investment | $6,749,000 | $6,749,000 | $6,766,000 | $6,326,000 |
| Other | ||||
| Ordinary Shares Number | $81,120,931 | $78,397,380 | $63,601,015 | $48,477,209 |
| Share Issued | $81,120,931 | $78,397,380 | $63,601,015 | $48,477,209 |
| Tangible Book Value | $-6,371,000 | $67,006,000 | $137,059,000 | $115,661,000 |
| Invested Capital | $68,544,000 | $141,048,000 | $210,296,000 | $188,771,000 |
| Working Capital | $-30,794,000 | $62,735,000 | $92,544,000 | $72,267,000 |
| Capital Lease Obligations | $14,349,000 | $11,576,000 | $17,145,000 | $21,215,000 |
| Total Capitalization | $43,896,000 | $141,048,000 | $210,296,000 | $188,771,000 |
| Additional Paid In Capital | $808,021,000 | $773,565,000 | $693,841,000 | $581,893,000 |
| Capital Stock | $3,000 | $3,000 | $2,000 | $2,000 |
| Common Stock | $3,000 | $3,000 | $2,000 | $2,000 |
| Non Current Deferred Revenue | $65,120,000 | $57,576,000 | $34,017,000 | $27,436,000 |
| Long Term Capital Lease Obligation | $11,460,000 | $7,523,000 | $12,952,000 | $17,331,000 |
| Long Term Provisions | $1,399,000 | $2,821,000 | $2,401,000 | $2,179,000 |
| Current Deferred Revenue | $1,776,000 | $4,827,000 | $2,926,000 | $15,123,000 |
| Current Capital Lease Obligation | $2,889,000 | $4,053,000 | $4,193,000 | $3,884,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $12,810,000 | $11,197,000 | $12,129,000 | $9,600,000 |
| Current Accrued Expenses | $20,083,000 | $16,217,000 | $30,510,000 | $30,218,000 |
| Investments And Advances | $6,749,000 | $6,749,000 | $6,766,000 | $6,326,000 |
| Net PPE | $141,933,000 | $135,652,000 | $156,238,000 | $154,093,000 |
| Accumulated Depreciation | $-52,629,000 | $-42,303,000 | $-33,325,000 | $-20,393,000 |
| Gross PPE | $194,562,000 | $177,955,000 | $189,563,000 | $174,486,000 |
| Leases | $107,793,000 | $99,371,000 | $103,082,000 | $91,053,000 |
| Other Properties | $77,760,000 | $70,534,000 | $78,377,000 | $76,004,000 |
| Machinery Furniture Equipment | $9,009,000 | $8,050,000 | $8,104,000 | $7,429,000 |
| Properties | $0 | $0 | $0 | $0 |
| Treasury Shares Number | - | - | $0 | - |
Fetched: 2026-06-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-50,595,000 | $-109,450,000 | $-125,539,000 | $-118,061,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-46,359,000 | $-104,495,000 | $-105,365,000 | $-73,098,000 |
| Cash Flow From Continuing Operating Activities | $-46,295,000 | $-104,642,000 | $-105,371,000 | $-73,218,000 |
| Operating Gains Losses | $-1,791,000 | $-25,522,000 | $-63,489,000 | $9,452,000 |
| Investing Activities | ||||
| Capital Expenditure | $-4,236,000 | $-4,955,000 | $-20,174,000 | $-44,963,000 |
| Investing Cash Flow | $-4,107,000 | $23,479,000 | $34,034,000 | $-44,963,000 |
| Cash Flow From Continuing Investing Activities | $-4,107,000 | $23,479,000 | $34,034,000 | $-44,963,000 |
| Net Other Investing Changes | - | $28,434,000 | $54,208,000 | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $15,074,000 | $59,390,000 | $91,950,000 | $25,000,000 |
| Financing Cash Flow | $12,272,000 | $54,534,000 | $84,023,000 | $95,200,000 |
| Cash Flow From Continuing Financing Activities | $12,272,000 | $54,534,000 | $84,023,000 | $95,200,000 |
| Net Other Financing Charges | $-3,030,000 | $-4,856,000 | $-7,937,000 | $-5,031,000 |
| Net Common Stock Issuance | $15,074,000 | $59,390,000 | $91,950,000 | $25,000,000 |
| Common Stock Issuance | $15,074,000 | $59,390,000 | $91,950,000 | $25,000,000 |
| Cash Dividends Paid | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-29,000 | $0 | - | $0 |
| Interest Paid Supplemental Data | $11,036,000 | $12,029,000 | $13,054,000 | $329,000 |
| End Cash Position | $68,193,000 | $105,668,000 | $130,649,000 | $115,516,000 |
| Beginning Cash Position | $105,668,000 | $130,649,000 | $115,516,000 | $137,703,000 |
| Effect Of Exchange Rate Changes | $719,000 | $1,501,000 | $2,441,000 | $674,000 |
| Changes In Cash | $-38,194,000 | $-26,482,000 | $12,692,000 | $-22,861,000 |
| Proceeds From Stock Option Exercised | $257,000 | $0 | $10,000 | $231,000 |
| Net Issuance Payments Of Debt | $-29,000 | $0 | $0 | $75,000,000 |
| Net Long Term Debt Issuance | $-29,000 | $0 | - | $75,000,000 |
| Long Term Debt Payments | $-29,000 | $0 | - | $0 |
| Net Intangibles Purchase And Sale | $-410,000 | $0 | $54,208,000 | $0 |
| Purchase Of Intangibles | $-410,000 | $0 | - | - |
| Net PPE Purchase And Sale | $-3,697,000 | $-4,955,000 | $-20,174,000 | $-44,963,000 |
| Sale Of PPE | $129,000 | $0 | - | - |
| Purchase Of PPE | $-3,826,000 | $-4,955,000 | $-20,174,000 | $-44,963,000 |
| Change In Working Capital | $28,032,000 | $25,653,000 | $-983,000 | $9,621,000 |
| Change In Other Working Capital | $-731,000 | $26,664,000 | $-7,506,000 | $-15,920,000 |
| Change In Other Current Liabilities | $43,310,000 | $-3,958,000 | $-1,355,000 | $4,006,000 |
| Change In Other Current Assets | $-524,000 | $-1,543,000 | $-1,587,000 | $346,000 |
| Change In Payables And Accrued Expense | $-7,904,000 | $-3,221,000 | $1,948,000 | $16,347,000 |
| Change In Accrued Expense | $4,409,000 | $-13,959,000 | $-382,000 | $12,610,000 |
| Change In Payable | $-12,313,000 | $10,738,000 | $2,330,000 | $3,737,000 |
| Change In Account Payable | $-12,313,000 | $10,738,000 | $2,330,000 | $3,737,000 |
| Change In Prepaid Assets | $720,000 | $-1,328,000 | $2,690,000 | $-329,000 |
| Change In Inventory | $428,000 | $-387,000 | $0 | - |
| Change In Receivables | $-7,267,000 | $9,426,000 | $4,827,000 | $5,171,000 |
| Changes In Account Receivables | $-2,337,000 | $6,325,000 | $9,975,000 | $1,032,000 |
| Other Non Cash Items | $6,890,000 | $5,293,000 | $545,000 | $218,000 |
| Stock Based Compensation | $22,105,000 | $25,191,000 | $27,716,000 | $28,623,000 |
| Depreciation Amortization Depletion | $12,606,000 | $12,681,000 | $13,724,000 | $8,603,000 |
| Depreciation And Amortization | $12,606,000 | $12,681,000 | $13,724,000 | $8,603,000 |
| Amortization Cash Flow | $300,000 | $300,000 | $300,000 | $200,000 |
| Amortization Of Intangibles | $300,000 | $300,000 | $300,000 | $200,000 |
| Depreciation | $12,306,000 | $12,381,000 | $13,424,000 | $8,403,000 |
| Earnings Losses From Equity Investments | $0 | $17,000 | $6,000 | $0 |
| Net Foreign Currency Exchange Gain Loss | $-2,146,000 | $2,886,000 | $-9,300,000 | $9,452,000 |
| Gain Loss On Sale Of PPE | $355,000 | $9,000 | $-54,195,000 | $0 |
| Net Income From Continuing Operations | $-114,201,000 | $-147,791,000 | $-84,027,000 | $-129,615,000 |
| Asset Impairment Charge | - | $0 | $1,149,000 | $0 |
| Issuance Of Debt | - | - | $0 | $75,000,000 |
| Net Short Term Debt Issuance | - | - | $0 | $75,000,000 |
| Short Term Debt Issuance | - | - | $0 | $75,000,000 |
| Sale Of Intangibles | - | - | $54,208,000 | $0 |
| Interest Paid Cff | - | - | - | $-2,257,000 |
| Long Term Debt Issuance | - | - | - | $75,000,000 |
| Net Business Purchase And Sale | - | - | - | $0 |
| Purchase Of Business | - | - | - | $0 |
Fetched: 2026-06-23